{"component": "contracts", "props": {"contracts": [{"intro": "This Third Restated License Agreement for IL-21 Embodiments (as defined herein) (\u201cAgreement\u201d) is entered into as of December 3, 2009 (\u201cEffective Date\u201d) by and between ZymoGenetics, Inc., a Washington corporation (\u201cZGEN\u201d), and Novo Nordisk A/S, a Danish corporation (\u201cNN\u201d).", "id": "1mf3jKNeHq8", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312510043192/dex1037.htm", "category_name": "License Agreement", "company_name": "Zymogenetics Inc", "created": "March 1st, 2010", "published": true, "pretty": null, "uri": "/contracts/1mf3jKNeHq8", "title": "THIRD RESTATED LICENSE AGREEMENT FOR IL-21 EMBODIMENTS by and between ZymoGenetics, Inc., and Novo Nordisk A/S Effective Date: December 3, 2009", "group_id": "1mf3jKNeHq8", "group_samples": [{"label": "License Agreement (Zymogenetics Inc)", "uri": "/contracts/1mf3jKNeHq8", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each Party), and intending to be legally bound the Parties agree as follows:", "id": "23z02RHwF8I", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312507099646/dex101.htm", "category_name": "Manufacturing Services Agreement", "company_name": "Zymogenetics Inc", "created": "May 2nd, 2007", "published": true, "pretty": null, "uri": "/contracts/23z02RHwF8I", "title": "Manufacturing Services Agreement relating to rhThrombin Between Patheon Italia S.p.A. - and - ZymoGenetics, Inc. Effective: 1 January 2006 Signed: 19 January 2007", "group_id": "23z02RHwF8I", "group_samples": [{"label": "Manufacturing Services Agreement (Zymogenetics Inc)", "uri": "/contracts/23z02RHwF8I", "published": true}], "group_size": 1, "tags": [{"name": "Manufacturing Services Agreement", "type": "category", "uri": "/contracts/tagged/manufacturing-services-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Amendment (the \u201cAmendment\u201d) to License and Collaboration Agreement (the \u201cAgreement\u201d) by and between ZymoGenetics, Inc. (\u201cZGEN\u201d) and Bayer Schering Pharma AG (\u201cBayer\u201d) effective as of June 18, 2007 is made as of the 1st day of January 2010 (the \u201cEffective Date\u201d) by and among ZGEN, Bayer and ZymoGenetics, LLC, ZGEN\u2019s assignee under the Agreement (\u201cZymo\u201d). Capitalized terms not otherwise defined herein shall have those meanings set forth in the Agreement. The term, \u201cParty\u201d shall mean Bayer, ZGEN or Zymo and the term, \u201cParties\u201d means all of them.", "id": "2KlnHbqW1rc", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312510043192/dex1043.htm", "category_name": "License and Collaboration Agreement", "company_name": "Zymogenetics Inc", "created": "March 1st, 2010", "published": true, "pretty": null, "uri": "/contracts/2KlnHbqW1rc", "title": "Amendment To License and Collaboration Agreement", "group_id": "2KlnHbqW1rc", "group_samples": [{"label": "License and Collaboration Agreement (Zymogenetics Inc)", "uri": "/contracts/2KlnHbqW1rc", "published": true}], "group_size": 1, "tags": [{"name": "License and Collaboration Agreement", "type": "category", "uri": "/contracts/tagged/license-and-collaboration-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "", "id": "3fciDH4DuK7", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000103221002000018/dex1028.txt", "category_name": "Collaborative Development and Marketing Agreement", "company_name": "Zymogenetics Inc", "created": "January 10th, 2002", "published": true, "pretty": null, "uri": "/contracts/3fciDH4DuK7", "title": "EXHIBIT 10.28 COLLABORATIVE DEVELOPMENT AND MARKETING AGREEMENT", "group_id": "3fciDH4DuK7", "group_samples": [{"label": "Collaborative Development and Marketing Agreement (Zymogenetics Inc)", "uri": "/contracts/3fciDH4DuK7", "published": true}], "group_size": 1, "tags": [{"name": "Collaborative Development and Marketing Agreement", "type": "category", "uri": "/contracts/tagged/collaborative-development-and-marketing-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This AMENDMENT NO. 1 TO FACILITY AGREEMENT (this \u201cAmendment No. 1\u201d), dated as of October 22, 2008, is made by and among ZymoGenetics, Inc. and Deerfield Private Design Fund, L.P. and Deerfield Private Design International, L.P. (together the \u201cOriginal Deerfield Lenders\u201d) and Deerfield ZG Corporation (\u201cDZG\u201d).", "id": "3mc2zjPKFDG", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312510043192/dex1045.htm", "category_name": "Facility Agreement", "company_name": "Zymogenetics Inc", "created": "March 1st, 2010", "published": true, "pretty": null, "uri": "/contracts/3mc2zjPKFDG", "title": "AMENDMENT NO. 1 TO FACILITY AGREEMENT", "group_id": "3mc2zjPKFDG", "group_samples": [{"label": "Facility Agreement (Zymogenetics Inc)", "uri": "/contracts/3mc2zjPKFDG", "published": true}], "group_size": 1, "tags": [{"name": "Facility Agreement", "type": "category", "uri": "/contracts/tagged/facility-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "", "id": "3sybuqUIHkq", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000103221001501085/dex108.txt", "category_name": "Series B Co-Sale Agreement", "company_name": "Zymogenetics Inc", "created": "September 10th, 2001", "published": true, "pretty": null, "uri": "/contracts/3sybuqUIHkq", "title": "EXHIBIT 10.8 ZYMOGENETICS, INC. SERIES B CO-SALE AGREEMENT SERIES B CO-SALE AGREEMENT This SERIES B CO-SALE AGREEMENT (\"Agreement\") is entered into as of the _________________________ by and among the persons identified on Schedule A hereto...", "group_id": "3sybuqUIHkq", "group_samples": [{"label": "Series B Co Sale Agreement (Zymogenetics Inc)", "uri": "/contracts/3sybuqUIHkq", "published": true}], "group_size": 1, "tags": [{"name": "Series B Co-Sale Agreement", "type": "category", "uri": "/contracts/tagged/series-b-co-sale-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Washington", "type": "jurisdiction", "uri": "/contracts/tagged/washington-us"}]}, {"intro": "This TERMINATION AGREEMENT (this \u201cAgreement\u201d) is dated as of September 7, 2010 by and among ZymoGenetics, Inc., a Washington corporation (the \u201cCompany\u201d), Novo Nordisk A/S, a Danish corporation (\u201cNovo\u201d), Warburg, Pincus Equity Partners, L.P., a Delaware limited partnership (\u201cWPEP\u201d), Warburg, Pincus Netherlands Equity Partners I, C.V., a Netherlands limited partnership (\u201cWPNEP I\u201d), and Warburg, Pincus Netherlands Equity Partners III, C.V., a Netherlands limited partnership (\u201cWPNEP III\u201d and, collectively with WPEP and WPNEP I, the \u201cWPEP Parties\u201d). Each of the Company, Novo and the WPEP Parties are sometimes referred to herein individually, as a \u201cParty\u201d and, together as the \u201cParties.\u201d", "id": "44Kv1JT86Vf", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312510210085/dex99e20.htm", "category_name": "Termination Agreement", "company_name": "Zymogenetics Inc", "created": "September 15th, 2010", "published": true, "pretty": null, "uri": "/contracts/44Kv1JT86Vf", "title": "TERMINATION AGREEMENT", "group_id": "44Kv1JT86Vf", "group_samples": [{"label": "Termination Agreement (Zymogenetics Inc)", "uri": "/contracts/44Kv1JT86Vf", "published": true}], "group_size": 1, "tags": [{"name": "Termination Agreement", "type": "category", "uri": "/contracts/tagged/termination-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "Washington", "type": "jurisdiction", "uri": "/contracts/tagged/washington-us"}]}, {"intro": "", "id": "4FfgkWvKwm1", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312507230953/dex101.htm", "category_name": "Employment Agreement", "company_name": "Zymogenetics Inc", "created": "October 31st, 2007", "published": true, "pretty": null, "uri": "/contracts/4FfgkWvKwm1", "title": "FIRST AMENDMENT", "group_id": "4FfgkWvKwm1", "group_samples": [{"label": "Employment Agreement (Zymogenetics Inc)", "uri": "/contracts/4FfgkWvKwm1", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "This Co-Development/Co-Promotion and License Agreement relating to Type-3 Interferon Family is made as of the Effective Date by and among ZymoGenetics, Inc., a Washington corporation (\u201cZGEN\u201d), and ZymoGenetics, LLC, a Delaware limited liability company (\u201cZG LLC\u201d), and Bristol-Myers Squibb Company, a Delaware corporation (\u201cBMS\u201d). ZGEN and ZG LLC are referred to collectively as \u201cZymo\u201d, and any obligations attributed to Zymo hereunder shall apply jointly and severally to ZGEN and ZG LLC, however, as the owner of the Core Patents, ZG LLC has the sole right to receive the initial license fee, all Milestone Payments, all royalties and Net Profits.", "id": "4iS7KXMjDIF", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312509100189/dex101.htm", "category_name": "Co-Development/Co-Promotion and License Agreement", "company_name": "Zymogenetics Inc", "created": "May 6th, 2009", "published": true, "pretty": null, "uri": "/contracts/4iS7KXMjDIF", "title": "CO-DEVELOPMENT/CO-PROMOTION AND LICENSE AGREEMENT RELATING TO TYPE-3 INTERFERON FAMILY by and among ZymoGenetics, Inc. and ZymoGenetics, LLC and Bristol-Myers Squibb Company Execution Date: January 12, 2009", "group_id": "4iS7KXMjDIF", "group_samples": [{"label": "Co Development/Co Promotion and License Agreement (Zymogenetics Inc)", "uri": "/contracts/4iS7KXMjDIF", "published": true}], "group_size": 1, "tags": [{"name": "Co-Development/Co-Promotion and License Agreement", "type": "category", "uri": "/contracts/tagged/co-development-co-promotion-and-license-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "5O8zSJaoraI", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000103221001501085/dex1020.txt", "category_name": "Human Glucagon, Analogues of Human Glucagon, Analogs of Human Insulin Letter Agreement", "company_name": "Zymogenetics Inc", "created": "September 10th, 2001", "published": true, "pretty": null, "uri": "/contracts/5O8zSJaoraI", "title": "EXHIBIT 10.20 Amended and Restated Human Glucagon, Analogues of Human Glucagon, Analogs of Human Insulin Letter Agreement WHEREAS, ZGI, formerly an indirectly wholly owned subsidiary of NN, is engaged generally in the research and development of...", "group_id": "5O8zSJaoraI", "group_samples": [{"label": "Human Glucagon, Analogues of Human Glucagon, Analogs of Human Insulin Letter Agreement (Zymogenetics Inc)", "uri": "/contracts/5O8zSJaoraI", "published": true}], "group_size": 1, "tags": [{"name": "Human Glucagon, Analogues of Human Glucagon, Analogs of Human Insulin Letter Agreement", "type": "category", "uri": "/contracts/tagged/human-glucagon-analogues-of-human-glucagon-analogs-of-human-insulin-letter-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}]}, {"intro": "This Collaborative Data Sharing Agreement for IL-21 Protein (\u201cAgreement\u201d) is effective as of August 11, 2005 (the \u201cEffective Date\u201d) and is entered into by and between ZymoGenetics, Inc., a Washington corporation having a principal place of business at 1201 Eastlake Avenue East, Seattle, Washington 98102 (\u201cZGEN\u201d), and Novo Nordisk A/S, a Danish corporation having a principal place of business at Novo Alle, DK-2880, Bagsvaerd, Denmark (\u201cNN\u201d).", "id": "7JNAl4MruT1", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312505215661/dex102.htm", "category_name": "Collaborative Data Sharing and Cross-License Agreement", "company_name": "Zymogenetics Inc", "created": "November 3rd, 2005", "published": true, "pretty": null, "uri": "/contracts/7JNAl4MruT1", "title": "COLLABORATIVE DATA SHARING AND CROSS-LICENSE AGREEMENT FOR IL-21 PROTEIN by and between ZymoGenetics, Inc. and Novo Nordisk A/S Effective Date: August 11, 2005", "group_id": "7JNAl4MruT1", "group_samples": [{"label": "Collaborative Data Sharing and Cross License Agreement (Zymogenetics Inc)", "uri": "/contracts/7JNAl4MruT1", "published": true}], "group_size": 1, "tags": [{"name": "Collaborative Data Sharing and Cross-License Agreement", "type": "category", "uri": "/contracts/tagged/collaborative-data-sharing-and-cross-license-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "Washington", "type": "jurisdiction", "uri": "/contracts/tagged/washington-us"}]}, {"intro": "This TENDER AND SUPPORT AGREEMENT (this \u201cAgreement\u201d), dated as of September 7, 2010, is by and among BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (\u201cParent\u201d), ZEUS ACQUISITION CORPORATION, a Washington corporation and a wholly owned subsidiary of Parent (\u201cMerger Sub\u201d), and each of the entities set forth on Schedule A hereto (each, a \u201cShareholder\u201d).", "id": "7hEt1pKNx2v", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312510206912/dex22.htm", "category_name": "Tender and Support Agreement", "company_name": "Zymogenetics Inc", "created": "September 9th, 2010", "published": true, "pretty": null, "uri": "/contracts/7hEt1pKNx2v", "title": "FORM OF TENDER AND SUPPORT AGREEMENT", "group_id": "7hEt1pKNx2v", "group_samples": [{"label": "Tender and Support Agreement (Zymogenetics Inc)", "uri": "/contracts/7hEt1pKNx2v", "published": true}], "group_size": 1, "tags": [{"name": "Tender and Support Agreement", "type": "category", "uri": "/contracts/tagged/tender-and-support-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This AMENDMENT NO. 1 TO FACILITY AGREEMENT (this \u201cAmendment No. 1\u201d), dated as of October 22, 2008, is made by and among ZymoGenetics, Inc. and Deerfield Private Design Fund, L.P. and Deerfield Private Design International, L.P. (together the \u201cOriginal Deerfield Lenders\u201d) and Deerfield ZG Corporation (\u201cDZG\u201d).", "id": "88IokcWPIuJ", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312508248862/dex44.htm", "category_name": "Facility Agreement", "company_name": "Zymogenetics Inc", "created": "December 5th, 2008", "published": true, "pretty": null, "uri": "/contracts/88IokcWPIuJ", "title": "AMENDMENT NO. 1 TO FACILITY AGREEMENT", "group_id": "88IokcWPIuJ", "group_samples": [{"label": "Facility Agreement (Zymogenetics Inc)", "uri": "/contracts/88IokcWPIuJ", "published": true}], "group_size": 1, "tags": [{"name": "Facility Agreement", "type": "category", "uri": "/contracts/tagged/facility-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "This Separation Agreement and Release (\u201cAgreement\u201d) is made and entered into by and between Nicole Onetto, an individual (\u201cEmployee\u201d), and ZymoGenetics, Inc., a Washington corporation (\u201cEmployer\u201d), and sets forth the terms upon which Employer and Employee have agreed to end Employee\u2019s employment with Employer.", "id": "8EQrgIfQBnZ", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312509162192/dex103.htm", "category_name": "Separation Agreement", "company_name": "Zymogenetics Inc", "created": "August 3rd, 2009", "published": true, "pretty": null, "uri": "/contracts/8EQrgIfQBnZ", "title": "SEPARATION AGREEMENT AND RELEASE", "group_id": "8EQrgIfQBnZ", "group_samples": [{"label": "Separation Agreement (Zymogenetics Inc)", "uri": "/contracts/8EQrgIfQBnZ", "published": true}], "group_size": 1, "tags": [{"name": "Separation Agreement", "type": "category", "uri": "/contracts/tagged/separation-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "Washington", "type": "jurisdiction", "uri": "/contracts/tagged/washington-us"}]}, {"intro": "This License and Transfer Agreement for IL-21 Protein (\u201cAgreement\u201d) is effective as of January 16, 2009 (the \u201cEffective Date\u201d) and is entered into by and between ZymoGenetics, Inc., a Washington corporation having a principal place of business at 1201 Eastlake Avenue East, Seattle, Washington 98102 (\u201cZGEN\u201d), and Novo Nordisk A/S, a Danish corporation having a principal place of business at Novo Alle, DK-2880, Bagsvaerd, Denmark (\u201cNN\u201d).", "id": "8mRehnviZ0D", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312509100189/dex102.htm", "category_name": "License and Transfer Agreement", "company_name": "Zymogenetics Inc", "created": "May 6th, 2009", "published": true, "pretty": null, "uri": "/contracts/8mRehnviZ0D", "title": "License and Transfer Agreement for IL-21 Protein", "group_id": "8mRehnviZ0D", "group_samples": [{"label": "License and Transfer Agreement (Zymogenetics Inc)", "uri": "/contracts/8mRehnviZ0D", "published": true}], "group_size": 1, "tags": [{"name": "License and Transfer Agreement", "type": "category", "uri": "/contracts/tagged/license-and-transfer-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "Washington", "type": "jurisdiction", "uri": "/contracts/tagged/washington-us"}]}, {"intro": "This Agreement, effective as of October 4, 2004 (the \u201cEffective Date\u201d), is entered into by and among ZymoGenetics, Inc., a Washington corporation whose address is 1201 Eastlake Ave. East, Seattle, WA 98102 (\u201cZGEN\u201d), Novo Nordisk A/S, a Danish corporation whose address is Novo All\u00e9, DK-2880, Bagsvaerd, Denmark (\u201cNovo\u201d), and Novo Nordisk Health Care AG, a Swiss corporation and wholly-owned affiliate of Novo whose address is Andreasstrasse 15, 8050 Z\u00fcrich, Switzerland (\u201cNN\u201d). ZGEN and NN are sometimes referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "9AZFMIzJBJf", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312505049565/dex1045.htm", "category_name": "License Agreement", "company_name": "Zymogenetics Inc", "created": "March 14th, 2005", "published": true, "pretty": null, "uri": "/contracts/9AZFMIzJBJf", "title": "TO ZymoGenetics\u2019s Form 10-K For the Year Ended December 31, 2004", "group_id": "9AZFMIzJBJf", "group_samples": [{"label": "License Agreement (Zymogenetics Inc)", "uri": "/contracts/9AZFMIzJBJf", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This memorandum of understanding (\u201cMOU\u201d) is entered into as of October 5, 2010, by and among the parties in the action captioned styled In re ZymoGenetics, Inc. Shareholder Litigation, Lead Case No. 10-2-32389-9 (the \u201cAction\u201d), by and through their respective undersigned counsel. This MOU is intended to be and is a binding agreement among the parties, and the undersigned counsel represent and warrant that they have express authority to bind their clients. This MOU outlines the general terms of the Settlement (as defined herein) that are to be embodied, together with such other consistent terms as may be agreed by the parties, in a Stipulation (as defined herein) to be submitted for Court approval as set forth below.", "id": "9CGhRBOW6Cr", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312510223550/dex99a1l.htm", "category_name": "Memorandum of Understanding", "company_name": "Zymogenetics Inc", "created": "October 5th, 2010", "published": true, "pretty": null, "uri": "/contracts/9CGhRBOW6Cr", "title": "MEMORANDUM OF UNDERSTANDING", "group_id": "9CGhRBOW6Cr", "group_samples": [{"label": "Memorandum of Understanding (Zymogenetics Inc)", "uri": "/contracts/9CGhRBOW6Cr", "published": true}], "group_size": 1, "tags": [{"name": "Memorandum of Understanding", "type": "category", "uri": "/contracts/tagged/memorandum-of-understanding"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "THIS U.S. CO-PROMOTION AGREEMENT is made as of the 18th day of June, 2007 (the \u201cEffective Date\u201d) by and between ZymoGenetics, Inc., a corporation organized and existing under the laws of Washington State, U.S.A. (\u201cZGEN\u201d), and Bayer HealthCare LLC, a limited liability company organized and existing under the laws of Delaware (\u201cBayer\u201d). ZGEN and Bayer are sometimes referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "9dOVdPaH1zs", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312507167557/dex101.htm", "category_name": "u.s. Co-Promotion Agreement", "company_name": "Zymogenetics Inc", "created": "August 1st, 2007", "published": true, "pretty": null, "uri": "/contracts/9dOVdPaH1zs", "title": "BY AND BETWEEN ZYMOGENETICS, INC. AND BAYER HEALTHCARE LLC EFFECTIVE AS OF JUNE 18, 2007 the Securities and Exchange Commission pursuant to a request for confidential treatment.", "group_id": "9dOVdPaH1zs", "group_samples": [{"label": "u.s. Co Promotion Agreement (Zymogenetics Inc)", "uri": "/contracts/9dOVdPaH1zs", "published": true}], "group_size": 1, "tags": [{"name": "u.s. Co-Promotion Agreement", "type": "category", "uri": "/contracts/tagged/us-co-promotion-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This First Amendment to ZymoGenetics, Inc. Shareholders\u2019 Agreement (this \u201cAmendment\u201d), amending that certain Shareholder\u2019s Agreement among ZymoGenetics, Inc., a Washington corporation (the \u201cCompany\u201d), Novo Nordisk A/S, a Danish corporation, Novo Nordisk Pharmaceuticals, Inc., a Delaware corporation, Warburg Pincus Equity Partners, L.P., Warburg, Pincus Netherlands Equity Partners I, C.V., Warburg, Pincus Netherlands Equity Partners II, C.V. and Warburg, Pincus Netherlands Equity Partners III, C.V. , and the other persons listed on Schedule A thereto (collectively the \u201cInvestors\u201d), entered into as of November 10, 2000 (the \u201cShareholders\u2019 Agreement\u201d), is made by and among the Company and the undersigned Investors as of this 4th day of February, 2002. Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Shareholders\u2019 Agreement.", "id": "XdfH5Ogflj", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000103221002000768/dex101.htm", "category_name": "Shareholders\u2019 Agreement", "company_name": "Zymogenetics Inc", "created": "May 9th, 2002", "published": true, "pretty": null, "uri": "/contracts/XdfH5Ogflj", "title": "FIRST AMENDMENT TO ZYMOGENETICS, INC. SHAREHOLDERS\u2019 AGREEMENT", "group_id": "XdfH5Ogflj", "group_samples": [{"label": "Shareholders\u2019 Agreement (Zymogenetics Inc)", "uri": "/contracts/XdfH5Ogflj", "published": true}], "group_size": 1, "tags": [{"name": "Shareholders\u2019 Agreement", "type": "category", "uri": "/contracts/tagged/shareholders-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "This AGREEMENT, dated September 17, 2003, is between ZymoGenetics, Inc., a Washington corporation (\u201cCompany\u201d) and Fredrik Henell (\u201cExecutive\u201d).", "id": "a9Rsm0bJbh8", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312503079626/dex101.htm", "category_name": "Employment Agreement", "company_name": "Zymogenetics Inc", "created": "November 13th, 2003", "published": true, "pretty": null, "uri": "/contracts/a9Rsm0bJbh8", "title": "EMPLOYMENT AGREEMENT", "group_id": "a9Rsm0bJbh8", "group_samples": [{"label": "Employment Agreement (Zymogenetics Inc)", "uri": "/contracts/a9Rsm0bJbh8", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "Washington", "type": "jurisdiction", "uri": "/contracts/tagged/washington-us"}]}, {"intro": "This Amendment of May 18, 2004 (\u201cAmendment Agreement\u201d) to the Insulin Agreement and the 1987 Agreement (as defined below) is entered into between Novo Nordisk A/S, a Danish corporation having a principal place of business at Novo Alle, DK-2880, Bagsvaerd, Denmark (\u201cNovo Nordisk\u201d) and ZymoGenetics Inc., a Washington Corporation having a principal place of business at 1201 Eastlake Avenue East, Seattle, Washington 98102 (\u201cZGI\u201d).", "id": "aAidLjlypvE", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312504135946/dex103.htm", "category_name": "Insulin Agreement", "company_name": "Zymogenetics Inc", "created": "August 9th, 2004", "published": true, "pretty": null, "uri": "/contracts/aAidLjlypvE", "title": "Amendment to 6 August 1982 Insulin Agreement", "group_id": "aAidLjlypvE", "group_samples": [{"label": "Insulin Agreement (Zymogenetics Inc)", "uri": "/contracts/aAidLjlypvE", "published": true}], "group_size": 1, "tags": [{"name": "Insulin Agreement", "type": "category", "uri": "/contracts/tagged/insulin-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "This AMENDMENT NO. 1 TO ROYALTY AGREEMENT (this \u201cAmendment No. 1\u201d), dated as of October 22, 2008, is made by and among Deerfield Private Design Fund, L.P., a Delaware limited partnership (\u201cDesign Fund\u201d), Deerfield Private Design International, L.P., a British Virgin Islands limited partnership (\u201cDesign International\u201d), Deerfield ZG Corporation, a Delaware corporation (\u201cDeerfield ZG\u201d) and ZymoGenetics, Inc., a Washington corporation (\u201cZymoGenetics\u201d).", "id": "bICFGRZcAmv", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312508248862/dex48.htm", "category_name": "Royalty Agreement", "company_name": "Zymogenetics Inc", "created": "December 5th, 2008", "published": true, "pretty": null, "uri": "/contracts/bICFGRZcAmv", "title": "AMENDMENT NO. 1 TO ROYALTY AGREEMENT", "group_id": "bICFGRZcAmv", "group_samples": [{"label": "Royalty Agreement (Zymogenetics Inc)", "uri": "/contracts/bICFGRZcAmv", "published": true}], "group_size": 1, "tags": [{"name": "Royalty Agreement", "type": "category", "uri": "/contracts/tagged/royalty-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "", "id": "bjzjqMnHymB", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000103221001501085/dex93.txt", "category_name": "Share Transfer and Voting Agreement", "company_name": "Zymogenetics Inc", "created": "September 10th, 2001", "published": true, "pretty": null, "uri": "/contracts/bjzjqMnHymB", "title": "RECITALS", "group_id": "bjzjqMnHymB", "group_samples": [{"label": "Share Transfer and Voting Agreement (Zymogenetics Inc)", "uri": "/contracts/bjzjqMnHymB", "published": true}], "group_size": 1, "tags": [{"name": "Share Transfer and Voting Agreement", "type": "category", "uri": "/contracts/tagged/share-transfer-and-voting-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Washington", "type": "jurisdiction", "uri": "/contracts/tagged/washington-us"}]}, {"intro": "This Amendment is made to the ZymoGenetics Deferred Compensation Plan for Key Employees (the \u201cPlan\u201d) which was originally effective November 1, 1992 and most recently amended and restated effective November 1, 1997.", "id": "cAyqBJ2elmS", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312508104098/dex104.htm", "category_name": "Deferred Compensation Plan Amendment", "company_name": "Zymogenetics Inc", "created": "May 6th, 2008", "published": true, "pretty": null, "uri": "/contracts/cAyqBJ2elmS", "title": "THIRD AMENDMENT TO ZYMOGENETICS DEFERRED COMPENSATION PLAN FOR KEY EMPLOYEES", "group_id": "cAyqBJ2elmS", "group_samples": [{"label": "Deferred Compensation Plan Amendment (Zymogenetics Inc)", "uri": "/contracts/cAyqBJ2elmS", "published": true}], "group_size": 1, "tags": [{"name": "Deferred Compensation Plan Amendment", "type": "category", "uri": "/contracts/tagged/deferred-compensation-plan-amendment"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning the others, except to the extent that it knows or has reason to believe that such information is inaccurate. This Agreement may be executed in any number of counterparts and all such counterparts taken together shall constitute one and the same instrument.", "id": "dt40yM7jWYj", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000089914007001665/w100507b.txt", "category_name": "Filing Agreement", "company_name": "Zymogenetics Inc", "created": "October 5th, 2007", "published": true, "pretty": null, "uri": "/contracts/dt40yM7jWYj", "title": "Exhibit 99.1 AGREEMENT OF FILING OF SCHEDULE 13G The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G...", "group_id": "dt40yM7jWYj", "group_samples": [{"label": "Filing Agreement (Zymogenetics Inc)", "uri": "/contracts/dt40yM7jWYj", "published": true}], "group_size": 1, "tags": [{"name": "Filing Agreement", "type": "category", "uri": "/contracts/tagged/filing-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "", "id": "duCotC8nDgu", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000103221003000482/dex1029.txt", "category_name": "Collaborative Agreement", "company_name": "Zymogenetics Inc", "created": "March 28th, 2003", "published": true, "pretty": null, "uri": "/contracts/duCotC8nDgu", "title": "Word: Section of License Agreement for IL-21: --------------------------------- ----------------------------------------------- \"IL-21 Embodiment\" SECTION 1.6 ------------------------------------------------------------------------------- - \"IL-21...", "group_id": "duCotC8nDgu", "group_samples": [{"label": "Collaborative Agreement (Zymogenetics Inc)", "uri": "/contracts/duCotC8nDgu", "published": true}], "group_size": 1, "tags": [{"name": "Collaborative Agreement", "type": "category", "uri": "/contracts/tagged/collaborative-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "Washington", "type": "jurisdiction", "uri": "/contracts/tagged/washington-us"}]}, {"intro": "This Amendment No. 1 to Manufacturing Services Agreement relating to rhThrombin, dated as of December 3, 2007 (\u201cEffective Date\u201d), is entered into by and between Patheon Italia S.p.A. (\u201cPatheon\u201d) and ZymoGenetics, Inc., a Washington corporation (\u201cZGEN\u201d).", "id": "eSPiLSRhH8X", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312508043300/dex1049.htm", "category_name": "Manufacturing Services Agreement", "company_name": "Zymogenetics Inc", "created": "February 29th, 2008", "published": true, "pretty": null, "uri": "/contracts/eSPiLSRhH8X", "title": "Amendment No. 1 to Manufacturing Services Agreement relating to rhThrombin", "group_id": "eSPiLSRhH8X", "group_samples": [{"label": "Manufacturing Services Agreement (Zymogenetics Inc)", "uri": "/contracts/eSPiLSRhH8X", "published": true}], "group_size": 1, "tags": [{"name": "Manufacturing Services Agreement", "type": "category", "uri": "/contracts/tagged/manufacturing-services-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "This Strategic Alliance Agreement is made as of the Effective Date, October 12, 2004, by and between ZymoGenetics, Inc., a Washington corporation (\u201cZGEN\u201d), and Serono S.A., a Swiss corporation (\u201cSerono\u201d).", "id": "eTtFTs94ZfC", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312505049565/dex1044.htm", "category_name": "Strategic Alliance Agreement", "company_name": "Zymogenetics Inc", "created": "March 14th, 2005", "published": true, "pretty": null, "uri": "/contracts/eTtFTs94ZfC", "title": "STRATEGIC ALLIANCE AGREEMENT by and between ZymoGenetics, Inc. and Serono S.A. Effective Date: October 12, 2004", "group_id": "eTtFTs94ZfC", "group_samples": [{"label": "Strategic Alliance Agreement (Zymogenetics Inc)", "uri": "/contracts/eTtFTs94ZfC", "published": true}], "group_size": 1, "tags": [{"name": "Strategic Alliance Agreement", "type": "category", "uri": "/contracts/tagged/strategic-alliance-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This amendment (the \u201cAmendment\u201d) to the U.S. Co-Promotion Agreement (the \u201cAgreement\u201d) by and between ZymoGenetics, Inc. (\u201cZGEN\u201d) and Bayer HealthCare LLC (\u201cBayer\u201d) effective as of June 18, 2007 is made the 1st day of January 2010 (the \u201cEffective Date\u201d) by and among ZGEN, Bayer and ZymoGenetics, LLC, ZGEN\u2019s assignee under the Agreement (\u201cZymo\u201d). Capitalized terms not otherwise defined herein shall have those meanings set forth in the Agreement. The term, \u201cParty\u201d shall mean Bayer, ZGEN or Zymo and the term, \u201cParties\u201d means all of them.", "id": "epxJGap7otU", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312510043192/dex1041.htm", "category_name": "u.s. Co-Promotion Agreement", "company_name": "Zymogenetics Inc", "created": "March 1st, 2010", "published": true, "pretty": null, "uri": "/contracts/epxJGap7otU", "title": "Amendment to U.S. Co-Promotion Agreement", "group_id": "epxJGap7otU", "group_samples": [{"label": "u.s. Co Promotion Agreement (Zymogenetics Inc)", "uri": "/contracts/epxJGap7otU", "published": true}], "group_size": 1, "tags": [{"name": "u.s. Co-Promotion Agreement", "type": "category", "uri": "/contracts/tagged/us-co-promotion-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "THIS AGREEMENT dated as of February 3, 2005, is made and entered into by and between ZymoGenetics, Inc., a Washington corporation (the \u201cCompany\u201d), and Bruce L. A. Carter (the \u201cExecutive\u201d).", "id": "fptAGbkjdL8", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312505022000/dex101.htm", "category_name": "Employment Agreement", "company_name": "Zymogenetics Inc", "created": "February 8th, 2005", "published": true, "pretty": null, "uri": "/contracts/fptAGbkjdL8", "title": "AMENDED AND RESTATED EMPLOYMENT AGREEMENT", "group_id": "fptAGbkjdL8", "group_samples": [{"label": "Employment Agreement (Zymogenetics Inc)", "uri": "/contracts/fptAGbkjdL8", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "Washington", "type": "jurisdiction", "uri": "/contracts/tagged/washington-us"}]}, {"intro": "This AMENDMENT NO. 2 TO LEASE (this \u201cAmendment\u201d) is entered into as of the below date between ARE-1201/1208 EASTLAKE AVENUE, LLC, a Delaware limited liability company (\u201cLandlord\u201d) and ZYMOGENETICS, INC., a Washington corporation (\u201cTenant\u201d).", "id": "frGqAJzkOyD", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312504135946/dex101.htm", "category_name": "Lease", "company_name": "Zymogenetics Inc", "created": "August 9th, 2004", "published": true, "pretty": null, "uri": "/contracts/frGqAJzkOyD", "title": "AMENDMENT NO. 2 TO LEASE LAKE UNION STEAM PLANT BUILDING", "group_id": "frGqAJzkOyD", "group_samples": [{"label": "Lease (Zymogenetics Inc)", "uri": "/contracts/frGqAJzkOyD", "published": true}], "group_size": 1, "tags": [{"name": "Lease", "type": "category", "uri": "/contracts/tagged/lease"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}, {"intro": "THIS SUBLEASE AGREEMENT (hereinafter this \u201cSublease\u201d) is made and entered into as of June 1, 2006, between Softchoice Corporation, a corporation organized under the laws of Canada (\u201cSublandlord\u201d) and ZymoGenetics, Inc., a Washington corporation (\u201cSubtenant\u201d).", "id": "gIQB3SsxVoM", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312507043847/dex1039.htm", "category_name": "Sublease Agreement", "company_name": "Zymogenetics Inc", "created": "March 1st, 2007", "published": true, "pretty": null, "uri": "/contracts/gIQB3SsxVoM", "title": "SUBLEASE AGREEMENT", "group_id": "gIQB3SsxVoM", "group_samples": [{"label": "Sublease Agreement (Zymogenetics Inc)", "uri": "/contracts/gIQB3SsxVoM", "published": true}], "group_size": 1, "tags": [{"name": "Sublease Agreement", "type": "category", "uri": "/contracts/tagged/sublease-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "Washington", "type": "jurisdiction", "uri": "/contracts/tagged/washington-us"}]}, {"intro": "This ROYALTY AGREEMENT (this \u201cAgreement\u201d), dated June 26, 2008, is made by and between Deerfield Private Design Fund, L.P., a Delaware limited partnership (\u201cDesign Fund\u201d), and Deerfield Private Design International, L.P., a British Virgin Islands limited partnership (\u201cDesign International\u201d and together with Design Fund, \u201cDeerfield\u201d) and ZymoGenetics, Inc., a Washington corporation (\u201cZymoGenetics\u201d).", "id": "gXnG24TLzZm", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312508166461/dex104.htm", "category_name": "Royalty Agreement", "company_name": "Zymogenetics Inc", "created": "August 5th, 2008", "published": true, "pretty": null, "uri": "/contracts/gXnG24TLzZm", "title": "ROYALTY AGREEMENT", "group_id": "gXnG24TLzZm", "group_samples": [{"label": "Royalty Agreement (Zymogenetics Inc)", "uri": "/contracts/gXnG24TLzZm", "published": true}], "group_size": 1, "tags": [{"name": "Royalty Agreement", "type": "category", "uri": "/contracts/tagged/royalty-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Agreement is made as of September 22, 2005, among (\u201cLandlord\u201d), Teutsch Partners, Conoco Phillips Company, a Delaware corporation (\u201cTenant\u201d), and Zymogenetics, (\u201cSubtenant\u201d).", "id": "gZXPfgBQ6xY", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312505215661/dex104.htm", "category_name": "Landlord's Consent to Sublease", "company_name": "Zymogenetics Inc", "created": "November 3rd, 2005", "published": true, "pretty": null, "uri": "/contracts/gZXPfgBQ6xY", "title": "LANDLORD\u2019S CONSENT TO SUBLEASE", "group_id": "gZXPfgBQ6xY", "group_samples": [{"label": "Landlord's Consent to Sublease (Zymogenetics Inc)", "uri": "/contracts/gZXPfgBQ6xY", "published": true}], "group_size": 1, "tags": [{"name": "Landlord's Consent to Sublease", "type": "category", "uri": "/contracts/tagged/landlords-consent-to-sublease"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}, {"name": "Washington", "type": "jurisdiction", "uri": "/contracts/tagged/washington-us"}]}, {"intro": "", "id": "h5Ji8dpaMwG", "source_url": "https://www.sec.gov/Archives/edgar/data/1129425/000119312505215661/dex103.htm", "category_name": "Office Lease Agreement", "company_name": "Zymogenetics Inc", "created": "November 3rd, 2005", "published": true, "pretty": null, "uri": "/contracts/h5Ji8dpaMwG", "title": "ADDENDUM TO OFFICE LEASE AGREEMENT", "group_id": "h5Ji8dpaMwG", "group_samples": [{"label": "Office Lease Agreement (Zymogenetics Inc)", "uri": "/contracts/h5Ji8dpaMwG", "published": true}], "group_size": 1, "tags": [{"name": "Office Lease Agreement", "type": "category", "uri": "/contracts/tagged/office-lease-agreement"}, {"name": "Zymogenetics Inc", "type": "company", "uri": "/company/1129425/zymogenetics-inc"}, {"name": "Biological products, (no disgnostic substances)", "type": "industry", "uri": "/contracts/tagged/biological-products-no-disgnostic-substances"}]}], "next_curs": "CjEKEAoKZ3JvdXBfc2l6ZRICCAEKGQoIZ3JvdXBfaWQSDRoLaDVKaThkcGFNd0cYACAB", "cursor": "CjEKEAoKZ3JvdXBfc2l6ZRICCAEKGQoIZ3JvdXBfaWQSDRoLMWhIdzhkZ1JiTHEYACAB"}}